Nitroglycerin Fails to Prevent Radial Artery Occlusion irrespective of time of administration: PATENS Trial

Written By :  MD Bureau
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2022-03-29 05:45 GMT   |   Update On 2023-10-13 10:10 GMT
Advertisement

Transradial access (TRA) has grown to become the default access site. However, TRA is not without challenges and complications. TRA is technically more difficult with a longer learning curve and is associated with radial artery spasm and radial artery occlusion (RAO), particularly in females and elderly patients.

A recent study suggests that administration of nitroglycerin upon radial sheath insertion or right before sheath removal was shown not to be associated with a reduction in RAO rates. The study findings were published in the JACC: Cardiovascular Interventions on March 21, 2022.

Advertisement

Maintaining arterial blood flow while achieving hemostasis is probably the most important factor in reducing RAO. While radial artery occlusion was once considered a "unique" phenomenon, there is increasing recognition that it can pose a real challenge for patients and operators. As a result, new research findings coupled with growing experience can help to refine our approach to prevent RAO. To further explore the effect of nitroglycerine on ROA, Dr Roberto L. da Silva and his team conducted a study to evaluate whether administration of nitroglycerin at the beginning or end of a TRA procedure would preserve radial patency.

The researchers conducted a prospective, multicenter, randomized, double-blind, 2-by-2 factorial, placebo-controlled trial (PATENS trial) with 2,040 patients undergoing TRA. They randomized the patients to either 500 μg nitroglycerin or placebo; each arm was also sub-randomized to early (upon sheath insertion) or late (right before sheath removal) nitroglycerin administration to evaluate the superiority of nitroglycerin in the prevention of RAO with 24 hours on Doppler ultrasound.

Key findings of the study:

  • Among 2040 patients, the researchers observed that RAO occurred in 49 patients (2.4%). They noted that fifteen of these patients (30.6%) showed reestablishment of flow at 30 days.
  • They found that nitroglycerin, compared with placebo, did not reduce the risk for RAO at either of the 2-time points (early, 2.5% vs 2.3%; late, 2.3% vs 2.5%).
  • Upon multivariable analysis, they noted that the presence of spasm (OR: 3.53) and access achieved with more than 1 puncture attempt (OR: 2.58) were independent predictors of RAO.

The authors concluded, "The routine use of nitroglycerin was not associated with a reduction in the rate of RAO, regardless of the time of administration (at the beginning or end of the TRA procedure)."

In an accompanying editorial, Dr Ziyad Gazzhal and Omar Chaabo wrote, " It is our view, based on this study, that intra-arterial nitroglycerin is not necessary at the time of sheath removal, provided best practices for the prevention of RAO are followed methodically. However, we believe that the administration of vasodilator therapy is still warranted at the beginning of the transradial procedure to reduce the chance of radial spasm. Finally, the distal radial artery approach at the snuffbox has been associated with a significantly lower incidence of proximal RAO and this technique, which has advantages and limitations, continues to evolve"

For further information:

DOI: https://www.jacc.org/doi/10.1016/j.jcin.2022.02.026

Keywords:

Transradial access, radial artery occlusion, arterial spasms, PATENS trial, Nitroglycerin, Early initiation, Late initiation, Doppler, Transradial Catheterization, JACC: Cardiovascular Interventions.


Tags:    
Article Source :  JACC: Cardiovascular Interventions

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News